Evidence map›Paper›PMID 38071680›Full record

ReviewMolecular biotechnology2024

An Investigation into Cell-Free DNA in Different Common Cancers.

Samira Nafar, Kamran Hosseini, Negin Shokrgozar, Amir Yousef Farahmandi, Vahab Alamdari-Palangi, Ali Saber Sichani, Jafar Fallahi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Samira NafarMedical Genetic Department, Shiraz University of Medical Science, Shiraz, Iran.
Kamran HosseiniDepartment of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
Negin ShokrgozarHematology Research Center, Shiraz University of Medical Science, Shiraz, Iran.
Amir Yousef FarahmandiDepartment of English, Shiraz University of Medical Sciences, Shiraz, Iran.
Vahab Alamdari-PalangiDepartment of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
Ali Saber SichaniDepartment of Biology, Texas A&M University, College Station, TX, 77843, USA.
Jafar FallahiDepartment of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran. jafarf80@gmail.com.ORCID http://orcid.org/0000-0002-8485-9247
Shiraz University of Medical Sciences · IRShiraz University · IRTexas A&M University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diagnosis is the most important step in different diseases, especially in cancers and blood malignancies. There are different methods in order to better diagnose of cancer, but many of them are invasive and also, some of them are not useful for immediate diagnosis. Cell-free DNA (cfDNA) or liquid biopsy easily accessible in peripheral blood is one of the non-invasive prognostic biomarkers in various areas of cancer management. In fact, amounts of cfDNA in serum or plasma can be used for diagnosis. In this review, we have considered some cancers such as hepatocellular carcinoma, lung cancer, breast cancer, and hematologic malignancies to compare the various methods of cfDNA diagnosis.

Indexed as

Biomarkers, TumorCirculating Tumor DNANeoplasmsHumansLiquid BiopsyBiomarkers, TumorCirculating Tumor DNABiomarkerCancerCell-free DNA

Identifiers

PMID38071680
OpenAlexW4389515978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.